News

Richmond, Va. (April 5, 2018) – Kaléo, a privately-held pharmaceutical company, today announced two new initiatives to help further expand access to EVZIO® (naloxone HCl injection, USP) Auto-Injector in support of the Surgeon General’s Advisory on Naloxone and Opioid Overdose emphasizing the importance of naloxone:

• Effective today— Through kaléo’s new “Virtual Standing Order” program, those with commercial insurance, without a prescription, can receive EVZIO at no cost by calling 1-877-883-8946 to talk to a pharmacist and arrange delivery of naloxone directly to their home. The Virtual Standing Order is now available for patients in six states as part of the initial pilot program: Arizona, California, Colorado, Missouri, Nevada and Ohio. Kaléo plans to expand the Virtual Standing Order program to additional states.
• Also effective today, kaléo is introducing a direct purchase price of $180 per auto-injector of EVZIO ($360 per pack of two auto injectors and a trainer) to all federal and state government agencies and tribes who purchase the product directly from kaléo, including those agencies who receive federal grant funding to address the opioid overdose epidemic. To obtain more information, please visit evzio.com/patient/direct-purchase.
  In addition, commercially-insured patients who are being treated by a healthcare provider and receive a prescription can continue to obtain EVZIO for $0 out of pocket through kaléo’s EVZIO2YOU program. Kaléo will also continue to donate product through the kaléo Cares Product Donation Program, which has donated, free of charge, more than 320,000 EVZIO naloxone auto-injectors nationwide to qualifying non-profits and first responders demonstrating need. For a complete summary of the comprehensive access program (including the terms and conditions) for EVZIO, visit www.evzio.com/patient/evzio2you.

In speaking about naloxone today, the surgeon general stated, “It is time to make sure more people have access to this lifesaving medication, because 77 percent of opioid overdose deaths occur outside of a medical setting and more than half occur at home.”

EVZIO—an auto-injector designed to be easy to use—provides simple, on-the-spot voice and visual guidance to help those with no medical training administer naloxone during an opioid overdose. EVZIO is not a substitute for emergency medical care.

The two initiatives announced today expand upon kaléo’s commitment to help ensure broad access to EVZIO. In 2016, kaléo created a first-of-its-kind access program for EVZIO, which allows the more than 200 million Americans with commercial insurance and a prescription—even those who have high-deductible health plans—to receive EVZIO for $0 out-of-pocket.  Even in cases where a patient’s commercial insurance does not cover EVZIO, kaléo ensures that they can obtain it for absolutely nothing out of pocket. Kaléo stands ready to work with government agencies, physicians, advocacy groups, and managed care organizations to ensure broad, affordable access to EVZIO.

“We are proud to support the Surgeon General’s Advisory on Naloxone and Opioid Overdose,” said Spencer Williamson, CEO of kaléo. “If we empower more patients to have access to this potentially life-saving medicine, we believe that EVZIO may help reduce the number of tragic deaths from opioid overdose across the nation.”

To view the full article, please click here.